Satellos Bioscience Inc (TSX:MSCL) Stock News, Headlines & Updates
Satellos Bioscience Inc Stock News from GuruFocus
- 1
Aug 19, 2024
Satellos Announces Acceptance of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247
Business Wire • 8:00am
Aug 12, 2024
Satellos Announces Q2 2024 Financial Results and Updated Canine Data
Business Wire • 7:00am
Aug 08, 2024
Satellos Receives Rare Pediatric Disease Designation from the U.S. FDA for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
Business Wire • 7:00am
Jul 11, 2024
Satellos Announces Submission of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247
Business Wire • 7:00am
Jul 02, 2024
Satellos Presents Preliminary Data Showing Muscle Repair and Regeneration from SAT-3247 Treatment in Canine Model of Duchenne Muscular Dystrophy (“DMD”)
Business Wire • 7:00am
Jun 27, 2024
Satellos Announces Presentation at Parent Project Muscular Dystrophy (PPMD) 30th Annual Conference
Business Wire • 7:00am
- 1
Show
Entries
Headlines
Total 0- 1
No recent news